BC Extra | Dec 13, 2019
Company News

Novartis gains CHMP support for Eylea competitor in wet AMD

EMA's CHMP issued a positive opinion for Novartis’ Beovu brolucizumab in its December roundup of opinions, none of which were negative. The agency backed an MAA from Novartis AG (NYSE:NVS; SIX:NOVN) for Beovu to treat...
BC Innovations | Nov 22, 2019
Product Development

The quiet disrupters: DNA-encoded and RNA-encoded antibodies

A new approach to streamlining biologics manufacturing could soon catch on--encoding the therapies in DNA or RNA, which enjoins the patient to produce the proteins in vivo . While the biggest upside may be the speed...
BC Extra | Nov 6, 2019
Company News

Biogen expanding biosimilars deal for eye therapies, anti-TNFs

As it continues to rely on biosimilars as a growth driver, Biogen has expanded its deal with Samsung Bioepis to include two new ocular biosimilars in certain major markets, as well as rights in China...
BC Extra | Oct 8, 2019
Company News

Oct. 8 Company Quick Takes: Novartis’ anti-VEGF approved for AMD; plus Merck-4D, Acorda, Clinuvel and Puma

Novartis’ Eylea competitor approved  FDA approved Beovu brolucizumab-dbll from Novartis AG (NYSE:NVS; SIX:NOVN) to treat wet age-related macular degeneration. In the Phase III HAWK and HARRIER trials, the anti-VEGF single-chain antibody fragment led to vision...
BioCentury | Oct 5, 2019
Finance

Seeking bright spots in 4Q19 amid continued underperformance

Biotech watchers are hoping a busy fourth quarter of data readouts, regulatory actions and IPOs will provide some bright spots to counteract the sector’s continued overall underperformance, which is not expected to improve in 2020....
BC Extra | Sep 13, 2019
Clinical News

Sept. 12 Clinical Quick Takes: Celgene meets in Phase III for AML maintenance therapy; plus Roche, Tocagen, Adverum, Daiichi Sankyo, Apple, Navitor

On Phase III AML meet, Celgene to submit regulatory applications 1H20  Celgene Corp. (NASDAQ:CELG) plans to submit regulatory applications for CC-486 next half after the cytosine nucleoside analog met the primary and secondary endpoints in...
BC Innovations | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

As in vivo gene therapies continue notching approvals for rare monogenic diseases, the next frontier for the modality will be in treating complex indications without obvious genetic drivers. At least seven companies have clinical or...
BioCentury | Jun 14, 2019
Product Development

Despite senior management shake-up, Novartis’ pipeline is primed to deliver

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...
BC Extra | May 13, 2019
Company News

May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron

PeptiDream, JCR deal produces drug carriers for CNS delivery  The 2016 partnership between PeptiDream Inc. (Tokyo:4587) and JCR Pharmaceuticals Co. Ltd. (Tokyo:4552) has led to the development of constrained peptides that bind TFRC and are...
BioCentury | May 11, 2019
Product Development

Now grown up, independent biotechs bulk up their platforms with more modalities

As the incoming class of independent biotechs look to build on their clinical and commercial successes, a handful are expanding beyond the technology that got them there, bringing in new modalities to complement their platforms...
Items per page:
1 - 10 of 432